GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocuphire Pharma Inc (NAS:OCUP) » Definitions » Shares Outstanding (EOP)

Ocuphire Pharma (Ocuphire Pharma) Shares Outstanding (EOP) : 23.98 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ocuphire Pharma Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Ocuphire Pharma's shares outstanding for the quarter that ended in Dec. 2023 was 23.98 Mil.

Ocuphire Pharma's quarterly shares outstanding increased from Sep. 2023 (22.61 Mil) to Dec. 2023 (23.98 Mil). It means Ocuphire Pharma issued new shares from Sep. 2023 to Dec. 2023 .

Ocuphire Pharma's annual shares outstanding increased from Dec. 2022 (20.86 Mil) to Dec. 2023 (23.98 Mil). It means Ocuphire Pharma issued new shares from Dec. 2022 to Dec. 2023 .


Ocuphire Pharma Shares Outstanding (EOP) Historical Data

The historical data trend for Ocuphire Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocuphire Pharma Shares Outstanding (EOP) Chart

Ocuphire Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
7.09 10.88 18.85 20.86 23.98

Ocuphire Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.86 20.95 20.99 22.61 23.98

Competitive Comparison of Ocuphire Pharma's Shares Outstanding (EOP)

For the Biotechnology subindustry, Ocuphire Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocuphire Pharma's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocuphire Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Ocuphire Pharma's Shares Outstanding (EOP) falls into.



Ocuphire Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Ocuphire Pharma  (NAS:OCUP) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Ocuphire Pharma Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Ocuphire Pharma's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocuphire Pharma (Ocuphire Pharma) Business Description

Traded in Other Exchanges
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Executives
George Magrath officer: Chief Executive Officer 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel officer: SVP, Operations & Bus. Dev. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch director, officer: President and CEO 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J director 5130 ROUTE 212, WILLOW NY 12495
Jay Pepose director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton director 3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba officer: VP of Finance 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer director
Sean Ainsworth director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann officer: VP of Corp. Dev. & Ops & Sec. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price director 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky officer: President and CFO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732